Literature DB >> 16088136

The relation between homocysteine levels and development of Alzheimer's disease in mild cognitive impairment patients.

Sylvia Annerbo1, Lars-Olof Wahlund, Johan Lökk.   

Abstract

The aim of this study was to investigate over a 3-year period the connection between homocysteine (Hcy) levels and development of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI). Hcy was analyzed in 68 men, mean age 65 years, and 68 women, mean age 64 years. Age, sex, cobalamin, folate, creatinine, and thyroid profiles as well as results of Mini-Mental State Examination at the first visit to the memory investigation unit of a geriatric department were recorded from patient journals collected between 1992 and 1999. The total numbers of persons who converted to AD within a period of 3 years from initial investigation with baseline Hcy sampling was 12 of 46 (26%) males, and 18 of 50 women (36%). The total percentage of men and women converting to AD was 31%. Thirty-three percent of men with Hcy levels >20 micromol/l converted to AD. The corresponding figure for men with Hcy levels 20-17 micromol/l was 50%, whereas none of the 18 men with Hcy levels <17 micromol/l converted to AD. These differences were statistically significant. There was also a statistically significant difference between the percentage of women with Hcy levels >16 micromol/l who converted to AD (45%) as compared to those with Hcy levels <16 micromol/l who converted (21%). These findings are inconsistent with the results of other studies showing a positive correlation with hyperhomocysteinemia and occurrence of AD. However, our findings tentatively suggest a possible protective effect of low/normal Hcy levels on dementia conversion in MCI patients. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16088136     DOI: 10.1159/000087297

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  6 in total

1.  Cobalamin deficiency, hyperhomocysteinemia, and dementia.

Authors:  Steven F Werder
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

2.  Conversion from mild cognitive impairment to dementia: influence of folic acid and vitamin B12 use in the VITA cohort.

Authors:  I Blasko; M Hinterberger; G Kemmler; S Jungwirth; W Krampla; T Leitha; K Heinz Tragl; P Fischer
Journal:  J Nutr Health Aging       Date:  2012-08       Impact factor: 4.075

Review 3.  Homocysteine and Mild Cognitive Impairment: Are These the Tools for Early Intervention in the Dementia Spectrum?

Authors:  Z Ansari
Journal:  J Nutr Health Aging       Date:  2016-02       Impact factor: 4.075

4.  The relationship between associative learning, transfer generalization, and homocysteine levels in mild cognitive impairment.

Authors:  Ahmed A Moustafa; Doaa H Hewedi; Abeer M Eissa; Catherine E Myers; Hisham A Sadek
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

5.  Characteristics of TCM Constitution and Related Biomarkers for Mild Cognitive Impairment.

Authors:  Liying Tang; Zhuocheng Zou; Qiang Liu; Xiangming Deng; Jinlong Teng; Xiucheng Nong; Bihan Yu; Jinsong Liang; Lu Zhou; Qirong Li; Lihua Zhao
Journal:  Neuropsychiatr Dis Treat       Date:  2021-04-20       Impact factor: 2.570

6.  Blood levels of circulating methionine components in Alzheimer's disease and mild cognitive impairment: A systematic review and meta-analysis.

Authors:  Yan Zhao; Xinyi Dong; Bingyu Chen; Yizhou Zhang; Sijia Meng; Fangzhen Guo; Xiaojing Guo; Jialei Zhu; Haoyue Wang; Huixian Cui; Sha Li
Journal:  Front Aging Neurosci       Date:  2022-07-22       Impact factor: 5.702

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.